Compare IDEXX Laboratories, Inc. (IDXX) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Twilio Inc — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while Twilio Inc trades at $200.33 (market cap $31.15B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Twilio Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | TWLO | |
|---|---|---|
Market Cap | $44.48B | $31.15B |
Sector | Health | Technology |
52-Week High | $766.68 | $236.64 |
52-Week Low | $520.87 | $92.44 |
Enterprise Value | $45.38B | $29.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Twilio (TWLO) trades at $208.56, up 0.86% with a bullish technical outlook. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 6, 2026. Revenue grew to $5.07B in 2025, and net income turned positive at $33.83M. Analyst sentiment is strongly positive with a consensus price target of $223.00. Operating cash flow improved significantly to $1.00B in 2025, indicating strengthening financial health.
The outlook for Twilio is optimistic due to consistent earnings beats and robust revenue growth, though high valuation multiples pose risks. Key opportunities include AI-driven communication tools and margin expansion under new leadership. Risks include intense competition and execution challenges in sustaining profitability. Investors should monitor Q2 2026 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
